Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug trials either fail to meet their expected endpoints or show minimal statistical differentiation between active and placebo (i.e. efficaciousness). In other instances, failures might occur due to safety reasons. Clearly, a fundamental understanding of drug properties in the discovery and early phases of development as well as an accrual of knowledge regarding mechanisms of disease and clinical trial learnings is essential to increase productivity and success for ongoing drug development efforts.
Assuming that much of prior knowledge from prior drug development and trial efforts could be aggregated within some form of data management system, it has been proposed that systematic modeling and simulation-based trial designs could enhance the odds for successful commercialization of new drug entities. To that end, the application of micro-physiological systems (MPS) or organs-on-a-chip in drug discovery for the development of enhanced in-vitro models to simulate or predict in-vivo processes has begun to show a lot of potential.
While the utilization of MPS-based technologies could someday reap enormous scientific and regulatory benefits for patients, certain barriers must still be overcome which are impactful to the evolution and future implementation of these technologies. The intrinsic challenges as well as potential solutions will be discussed.
1. Learn about intrinsic challenges and potential solutions
2. Immediate outcomes of utilizing reliable in-vitro models